New drug ALT001 tested for rare brain disorder – safety first
NCT ID NCT07514923
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This early-stage study tests whether a new drug, ALT001, is safe for people with multiple system atrophy-cerebellar type (MSA-C), a rare brain disease that affects movement and balance. About 20 adults aged 30 to 75 with early-stage MSA-C will receive the drug and be closely monitored for side effects. The goal is to check safety and see if the drug might help control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY - CEREBELLAR SUBTYPE (MSA-C) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.